

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5141685

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	INNOVASSYNTH TECHNOLOGIES (INDIA) LTD. (MUMBAI, IN)	08/06/2018
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	CEYONE PHARMA,. LLC	
<b>Street Address:</b>	1200 S. CHURCH ST., SUITE 11	
<b>City:</b>	MOUNT LAUREL	
<b>State/Country:</b>	NEW JERSEY	
<b>Postal Code:</b>	08054	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	11278641
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(732)227-1513	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	7322430042	
<b>Email:</b>	btustin@ceyonepharma.com	
<b>Correspondent Name:</b>	BILL TUSTIN	
<b>Address Line 1:</b>	1200 S. CHURCH ST.	
<b>Address Line 2:</b>	SUITE 11	
<b>Address Line 4:</b>	MOUNT LAUREL, NEW JERSEY 08054	
<b>NAME OF SUBMITTER:</b>	BILL TUSTIN	
<b>SIGNATURE:</b>	/William F. Tustin/	
<b>DATE SIGNED:</b>	09/14/2018	
	This document serves as an Oath/Declaration (37 CFR 1.63).	
<b>Total Attachments: 6</b>		
source=Patent Sale Agreement and Supplementary Agreement - Assignment of Patent 20180602 and 20180806#page1.tif		
source=Patent Sale Agreement and Supplementary Agreement - Assignment of Patent 20180602 and 20180806#page2.tif		
source=Patent Sale Agreement and Supplementary Agreement - Assignment of Patent 20180602 and 20180806#page3.tif		

source=Patent Sale Agreement and Supplementary Agreement - Assignment of Patent 20180602 and 20180806#page4.tif

source=Patent Sale Agreement and Supplementary Agreement - Assignment of Patent 20180602 and 20180806#page5.tif

source=Patent Sale Agreement and Supplementary Agreement - Assignment of Patent 20180602 and 20180806#page6.tif

Exhibit B

ASSIGNMENT OF PATENT

For good and valuable consideration, the receipt of which is hereby acknowledged, Innovassynth Technologies (India) Ltd., with a place of business at Old Mumbai Pune Road, Khopoli- 410203 (hereinafter referred to as the "Assignor") does hereby sell, assign, transfer and convey unto Shore Pharma LLC, ("Shore Pharma"), with a place of business at 675 US highway 1 North Brunswick, USA 08902 (hereinafter referred to as the "Assignee") or its designees, all of Assignor's entire right, title and interest in and to (a) U.S. Patent No. 7,534,911, Serial No. 11/278,641, filed on April 4, 2006, issued on May 19, 2009, entitled, Process for the preparation of Isosulphan Blue; (b) all reissues, reexaminations, continuations, continuations-in-part, divisionals and extensions of such patent, including any resulting patents issuing from any or all of the foregoing; and (c) foreign counterparts, if any, to any or all of the foregoing, including without limitation utility models, design patents, certificates of invention and equivalent rights worldwide; (collectively the "*Patent*");

The Assignor hereby also sells, assigns, transfers, and conveys to the Assignee, all right, title and interest in and to all:


- a. inventions, invention disclosures, and discoveries described in the Patent to the extent that such inventions, invention disclosures and discoveries could be claimed in the Patent; and
- b. causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights under, or on account of, any of the Patent, including, without limitation, all causes of action and other enforcement rights for (i) damages, (ii) injunctive relief, and (iii) any other remedies of any kind for past, current and future infringement, and (iv) rights to collect royalties or other payments under or on account of any of the Patent and/or any of the foregoing.

Assignor also hereby authorizes the United States Patent and Trademark Office to transfer ownership of the Patent on its records from the Assignor to the Assignee as to the entire interest therein.

The terms and conditions of this Assignment shall inure to the benefit of and

2018052302

21



PATENT

REEL: 046877 FRAME: 0228

Patent Assignment Agreement  
Privileged & Confidential

be binding upon the Assignee, its successors, assigns and other legal representatives, and shall inure to the benefit of and be binding upon Assignor, its successor, assigns and other legal representatives.

IN WITNESS WHEREOF this Assignment of Patent is executed on  
2<sup>nd</sup> June, 2018.

ASSIGNOR:

Innovassynth Technologies (India) Ltd

By: [Signature]

Name: Dr. B Sahu

Title: CEO & PRESIDENT

[Signature]  
Plotted: 1/1/2018

[Signature]  
Shore Pharma.


Sworn to and subscribed before me this 18 day of June, 2018.

Notary Public:


[Signature] (Seal)

My Commission Expires: July 08, 2022

Jurisdiction: State of New Jersey



2018052302



## SUPPLEMENTARY AGREEMENT FOR ASSIGNMENT OF PATENT

This supplemental agreement for assignment of patent is executed on August 6<sup>th</sup> 2018 between

Innovassynth Technologies (India) Limited, (CIN: U24110MH2001PLC134105) having its registered office at Old Mumbai -Pune Road, Khopoli Raigarh MH 410203 IN (hereinafter referred as Assignor) and

Shore Pharma LLC, with a place of business at 675 US highway 1, North Brunswick, NJ, USA 08902, (hereinafter referred to as the "Consenting party") and

Ceyone pharma LLC, with place of business at 1200 S Church St, Ste 11, Mount Laurel, NJ, USA 08054, (hereinafter referred to as the "Assignee")

The Assignor, Shore Pharma and Assignee may be referred to individually as a "Party" or collectively as the "Parties."

### WHEREAS

Patent sale agreement executed dated 02<sup>nd</sup> June, 2015 which was amended on 03, August, 2018 further assigning the patent to any third party. A original copy attached herein in Exhibit A and the amended deed in Exhibit B for the total consideration as follows:

1. [REDACTED] payable immediately on execution of the original patent sale agreement
2. [REDACTED] payable immediately upon obtaining approval of the product from U. S Food and Drug Administration (USFDA)

AND WHEREAS , after execution of the original agreement, Shore Pharma transferred first instalment of [REDACTED] on 05<sup>th</sup> July, 2018 and requested to re-assign the patent to Ceyone Pharma LLC, their group company on the same terms and conditions as mentioned in the original agreement.

### NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:


Effective as of this supplemental agreement, Assignor shall sell, transfers, convey, assigns and deliver all of its rights, title, and interest in and to the Patent and additional rights as provided in the Original agreement to the assignee.

1. All the terms & Conditions, rights & obligations mentioned in the Original Agreement shall be binding on the Assignor and Assignee as applicable to consenting party.
2. The Balance consideration of the original agreement [REDACTED] shall be payable by Assignee immediately upon obtaining approval of product from USFDA as per original agreement. If Assignee fails to make payment Assigner shall have right to recover the amount from Consenting party.


3. Shore pharma LLC shall not have any claim, rights or title against Innovassynth Technologies(India) Limited.

IN WITNESS THEREOF, the parties have executed this agreement as of the date first above written.

For Innovassynth Technologies (India) Limited

  
Dr. B Sahu, CEO & President

For Shore Pharma LLC



For Ceyone Pharma LLC,



## AMENDMENT AGREEMENT FOR ASSIGNMENT OF PATENT

This AMENDMENT agreement for assignment of patent is executed on August, 6<sup>th</sup> 2018 between

Innovassynth Technologies (India) Limited, (CIN: U24110MH2001PLC134105) having its registered office at Old Mumbai -Pune Road, Khopoli Raigarh MH 410203 IN (hereinafter referred as Assignor) and Shore Pharma LLC, with a place of business at 675 US highway 1, North Brunswick, NJ, USA 08902(hereinafter referred to as the "Assignee") and

The Assignor and Assignee may be referred to individually as a "Party" or collectively as the "Parties."

The agreement is amended as follows:

### Clause No.1: Definitions:

Addition of Definition of Assignee-

Assignee means Shore Pharma LLC or any other person or entity which is nominated by assignee subject to consent of assignor in writing.

### Clause No.2: Assignment of Patent and Additional Rights:


Sub-clause (a) of Clause 2, new clause shall be substituted:

- a. Effective as of the effective date, the Assignor sells, transfers, conveys, assigns, and delivers to the assignee or any other person or entity nominated by Shore Pharma LLC and the same is accepted & assumes all rights, title and interest of the assignor in and to the patent.


In event of Shore Pharma LLC assigns the patent to third party (Ceyone Pharma LLC), it shall be effected through execution of tri-partite agreement between Innovassynth Technologies (India) Limited, Shore Pharma LLC and proposed assignee Ceyone Pharma LLC, on the same terms as mentioned original patent sale agreement dated 2<sup>nd</sup> June, 2018

IN WITNESS THEREOF, the parties have executed this agreement as of the date first above written.


For Innovassynth Technologies (India) Limited

  
Dr. B Sahu, CEO & President

For Shore Pharma LLC

A handwritten signature in black ink, appearing to be "R. G. L.", written over a horizontal dotted line.

For Cayone Pharma LLC

A handwritten signature in black ink, appearing to be "A. H. J.", written over a horizontal dotted line.